NCT06694766 VAC-SIP-YF (Vaccination- Safety & Immunogenicity During Pregnancy- Yellow Fever)
| NCT ID | NCT06694766 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Pasteur |
| Condition | Yellow Fever Vaccine |
| Study Type | INTERVENTIONAL |
| Enrollment | 270 participants |
| Start Date | 2025-03-24 |
| Primary Completion | 2028-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 270 participants in total. It began in 2025-03-24 with a primary completion date of 2028-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to compare the immunogenicity induced by yellow fever vaccination administered during pregnancy with that induced by vaccination outside pregnancy, and to assess the maternal and fetal tolerance of this vaccination.
Eligibility Criteria
Inclusion Criteria: Common : * Person over 18 years of age at the time of the first yellow fever vaccination * Female gender * Oral consent obtained after subject has been informed * Subject covered by Social Security with the exception of Aide Médicale d'Etat Specific to both groups : * For women vaccinated during pregnancy (case): Primary yellow fever vaccination during pregnancy * For women vaccinated outside pregnancy (control): Primary yellow fever vaccination outside pregnancy Exclusion Criteria: Criteria common to both sections (tolerance and immunogenicity): * Subject having received a second yellow fever vaccination * Persons unable to give informed consent for participation * Women born in areas where yellow fever is endemic * Female adults under legal protection (guardianship or trusteeship) Specific criteria for participants in the immunogenicity section: * Medical condition imcompatible with 18.5 mL blood * Women who have not given written consent to participate in the study. immunogenicity
Contact & Investigator
Kaoutar JIDAR, MD
PRINCIPAL INVESTIGATOR
Medical Center of l'Institut Pasteur (CMIP)
Frequently Asked Questions
Who can join the NCT06694766 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Yellow Fever Vaccine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06694766 currently recruiting?
Yes, NCT06694766 is actively recruiting participants. Contact the research team at kaoutar.jidar@pasteur.fr for enrollment information.
Where is the NCT06694766 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT06694766 clinical trial?
NCT06694766 is sponsored by Institut Pasteur. The principal investigator is Kaoutar JIDAR, MD at Medical Center of l'Institut Pasteur (CMIP). The trial plans to enroll 270 participants.